Biomarker Technologies LLC To Begin Pilot Study Of A New Blood Test For Breast Cancer
10/19/2005 5:13:06 PM
PHOENIX--(BUSINESS WIRE)--March 23, 2005--
BT Test(TM) Provides Early Detection, Cost Effective Diagnostic Blood Test
Biomarker Technologies LLC, the worldwide technology provider of the blood diagnostic test for the detection of breast cancer called the BT Test(TM), announced today plans to begin a pilot study of the test in the United States beginning in April 2005.
The company is conducting the pilot study to verify its prior results and make final preparations for FDA clinical studies. The study will be a retrospective blind test with samples from healthy participants, those with untreated breast cancer, as well as those from a select group of other cancer conditions in order to demonstrate the differentiation capabilities of the test. In initial studies involving more than 250 subjects, the BT Test successfully identified non-treated breast cancer in women with a greater than 95% sensitivity and specificity, outperforming mammography.
comments powered by